Author

R. Vera

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1

Frequent Co-Authors

D. Escors· 3 shared G. Kochan· 3 shared H. Arasanz· 3 shared A. Bocanegra· 2 shared G. Fernandez-Hinojal· 2 shared L. Teijeira· 2 shared M. Gato· 2 shared M. J. Lecumberri· 2 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. Escors

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

HUMAN PANCREATIC CANCER CELLS UNDERGO PROFOUND METABOLIC REPROGRAMMING TOWARDS CELLULAR STEMNESS AS ADAPTATION TO INHIBITION OF THE AKT PATHWAY

H. Arasanz, C. Hernandez, A. Bocanegra, L. Chocarro, M. Zuazo, M. Gato, K. Ausin, E. Santamaria, J. Fernandez, G. Fernandez, E. Monasterio, C. Rodriguez, I. Blanco, R. Vera, D. Escors, G. Kochan

This study shows that pancreatic cancer cells adapt to AKT pathway inhibition by reprogramming metabolism and acquiring stemness traits, which can be targeted with combined therapy.

bioRxiv · Apr 1, 2020 · PreprintCancer Biology

Functional systemic CD4 immunity is a differential factor for clinical responses to PD-L1/PD-1 blockade therapy in lung cancer

M. Zuazo, H. Arasanz, G. Fernandez-Hinojal, M. J. Garcia-Granda, M. Gato, A. Bocanegra, B. Hernandez, M. Martinez, L. Teijeira, I. Morilla, M. J. Lecumberri, A. Fernandez de Lascoiti, R. Vera, G. Kochan, D. Escors

This study identifies functional systemic CD4 immunity as a key predictor of response to PD-L1/PD-1 blockade therapy in lung cancer patients.

bioRxiv · Jan 9, 2019Cancer Biology

Highly differentiated CD4 T cells Unequivocally Identify Primary Resistance and Risk of Hyperprogression to PD-L1/PD-1 Immune Checkpoint Blockade in Lung Cancer

M. Zuazo-Ibarra, H. Arasanz, G. Fernandez-Hinojal, M. Gato-Canas, B. Hernandez-Marin, M. Martinez-Aguillo, M. J. Lecumberri, A. Fernandez, L. Teijeira, R. Vera, G. Kochan, D. Escors

The paper identifies baseline circulating highly-differentiated CD4 T cells as predictors of response or hyperprogression to PD-L1/PD-1 blockade therapy in lung cancer patients.

bioRxiv · May 22, 2018Cancer Biology